WS
NVIV

Wedbush Securities’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Wedbush Securities’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,260
Closed -$116K – 1043
2020
Q3 		$116K Buy
3,260
+1,429
+78% +$52.8K 0.01% 814
2020
Q2 		$72K Buy
1,831
+693
+61% +$27K 0.01% 884
2020
Q1 		$48K Buy
+1,138
New +$161K 0.01% 824
2019
Q3 		– Sell
-22
Closed -$12K – 1059
2019
Q2 		$12K Buy
+22
New +$19.3K ﹤0.01% 978
2018
Q4 		– Sell
-52
Closed -$78K – 972
2018
Q3 		$78K Buy
52
+30
+136% +$44.2K 0.01% 853
2018
Q2 		$28K Buy
22
+17
+340% +$93.3K ﹤0.01% 856
2018
Q1 		$50K Hold
5
– – 0.01% 783
2017
Q4 		$76K Buy
5
+2
+67% +$46.3K 0.01% 804
2017
Q3 		$73K Buy
+3
New +$92.2K 0.01% 793

Other funds holding NVIV

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities's NVIV Position: Q4 2020 in Review

Wedbush Securities sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2020, closing a stake of 3,260 shares — an estimated $116K sold.

Wedbush Securities first reported a position in NVIV in Q3 2017 and held it in 9 quarters. The position peaked at $116K in Q3 2020. 11 funds tracked by Wall St. Rank hold NVIV as of Q4 2020.

  • Wedbush Securities reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 3,260 InVivo Therapeutics Holdings Corp shares in Q4 2020, an estimated $116K.
  • Wedbush Securities first reported a position in InVivo Therapeutics Holdings Corp in Q3 2017 and held it in 9 quarters.
  • Wedbush Securities's InVivo Therapeutics Holdings Corp position peaked at $116K in Q3 2020.
  • 11 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.